 | • レポートコード：MRC2304D085 • 出版社/出版日：Transparency Market Research / 2023年1月25日 • レポート形態：英文、PDF、217ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、新型コロナウイルス感染症用ワクチンの世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、市場動向、市場分析＆予測、ワクチン種類別（mRNA、ウイルスベクターワクチン、その他）分析、年齢層別（12歳~18歳、18歳以上）分析、流通チャンネル別（政府機関、病院＆クリニック、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、Pfizer-BioNTech、Moderna、AstraZeneca、Johnson & Johnson、Sinovac、Sinopharm、Bharat Biotech、Serum Institute of India、Novavax、Gamaleya Research Institute、CanSino Biologics、CureVac、GlaxoSmithKline、Sanofi-GSKなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・市場動向 ・市場分析＆予測 ・世界の新型コロナウイルス感染症用ワクチン市場規模：ワクチン種類別 - mRNAワクチンの市場規模 - ウイルスベクターワクチンの市場規模 - その他ワクチン種類の市場規模 ・世界の新型コロナウイルス感染症用ワクチン市場規模：年齢層別 - 12歳~18歳用新型コロナウイルス感染症用ワクチンの市場規模 - 18歳以上用新型コロナウイルス感染症用ワクチンの市場規模 ・世界の新型コロナウイルス感染症用ワクチン市場規模：流通チャンネル別 - 政府機関における市場規模 - 病院＆クリニックにおける市場規模 - その他における市場規模 ・世界の新型コロナウイルス感染症用ワクチン市場規模：地域別 - 北米の新型コロナウイルス感染症用ワクチン市場規模 - ヨーロッパの新型コロナウイルス感染症用ワクチン市場規模 - アジア太平洋の新型コロナウイルス感染症用ワクチン市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
COVID-19 Vaccine Market – Scope of Report
TMR’s report on the global COVID-19 vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global COVID-19 vaccine market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global COVID-19 vaccine market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the COVID-19 vaccine market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global COVID-19 vaccine market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global COVID-19 vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global COVID-19 vaccine market.
The report delves into the competitive landscape of the global COVID-19 vaccine market. Key players operating in the global COVID-19 vaccine market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global COVID-19 vaccine market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market COVID-19 vaccine.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global COVID-19 Vaccine Market
4. Market Overview
4.1. Introduction
4.1.1. COVID-19 vaccine Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global COVID-19 Vaccine Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Disease incidence and prevalence across the globe
5.2. Analysis of COVID-19 vaccination across the globe
5.3. Regulatory scenario across the globe/key countries
6. Global COVID-19 Vaccine Market Analysis and Forecast, by Vaccine Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine Type, 2017–2031
6.3.1. mRNA
6.3.2. Viral Vector Vaccines
6.3.2.1. Inactivated Virus Vaccines
6.3.2.2. Adenovirus Vaccines
6.3.2.3. Others
6.3.3. Others
6.4. Market Attractiveness, by Vaccine Type
7. Global COVID-19 Vaccine Market Analysis and Forecast, by Age Group
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Age Group, 2017–2031
7.3.1. 12 to 18
7.3.2. Above 18
7.4. Market Attractiveness, by Age Group
8. Global COVID-19 Vaccine Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Government Entities
8.3.2. Hospitals and Clinics
8.3.3. Others
8.4. Market Attractiveness, by Distribution Channel
9. Global COVID-19 Vaccine Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/Region
10. North America COVID-19 Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Vaccine Type, 2017–2031
10.2.1. mRNA
10.2.2. Viral Vector Vaccines
10.2.2.1. Inactivated Virus Vaccines
10.2.2.2. Adenovirus Vaccines
10.2.2.3. Others
10.2.3. Others
10.3. Market Value Forecast, by Age Group, 2017–2031
10.3.1. 12 to 18
10.3.2. Above 18
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Government Entities
10.4.2. Hospitals and Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Vaccine Type
10.6.2. By Age Group
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe COVID-19 Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Vaccine Type , 2017–2031
11.2.1. mRNA
11.2.2. Viral Vector Vaccines
11.2.2.1. Viral Vector Vaccines
11.2.2.2. Adenovirus Vaccines
11.2.2.3. Others
11.2.3. Others
11.3. Market Value Forecast, by Age Group, 2017–2031
11.3.1. 12 to 18
11.3.2. Above 18
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Government Entities
11.4.2. Hospitals and Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country, 2017–2031
11.5.1. U.K.
11.5.2. Germany
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Vaccine Type
11.6.2. By Age Group
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific COVID-19 Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vaccine Type, 2017–2031
12.2.1. mRNA
12.2.2. Viral Vector Vaccines
12.2.2.1. Inactivated Virus Vaccines
12.2.2.2. Adenovirus Vaccines
12.2.2.3. Others
12.2.3. Others
12.3. Market Value Forecast, by Age Group, 2017–2031
12.3.1. 12 to 18
12.3.2. Above 18
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Government Entities
12.4.2. Hospitals and Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Vaccine Type
12.6.2. By Age Group
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America COVID-19 Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vaccine Type, 2017–2031
13.2.1. mRNA
13.2.2. Viral Vector Vaccines
13.2.2.1. Inactivated Virus Vaccines
13.2.2.2. Adenovirus Vaccines
13.2.2.3. Others
13.2.3. Others
13.3. Market Value Forecast, by Age Group, 2017–2031
13.3.1. 12 to 18
13.3.2. Above 18
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Government Entities
13.4.2. Hospitals and Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Vaccine Type
13.6.2. By Age Group
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa COVID-19 Vaccine Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vaccine Type, 2017–2031
14.2.1. mRNA
14.2.1.1. Inactivated Virus Vaccines
14.2.1.2. Adenovirus Vaccines
14.2.1.3. Others
14.2.2. Viral Vector Vaccines
14.2.3. Others
14.3. Market Value Forecast, by Age Group, 2017–2031
14.3.1. 12 to 18
14.3.2. Above 18
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Government Entities
14.4.2. Hospitals and Clinics
14.4.3. Others
14.5. Market Value Forecast, by Country, 2017–2031
14.5.1. GCC countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Vaccine Type
14.6.2. By Age Group
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis by Company (2021)
15.3. Company Profiles
15.3.1. Pfizer-BioNTech
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Vaccine Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Moderna
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Vaccine Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. AstraZeneca
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Vaccine Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Johnson & Johnson
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Vaccine Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Sinovac
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Vaccine Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Sinopharm
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Vaccine Type Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Bharat Biotech
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Vaccine Type Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Serum Institute of India
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Vaccine Type Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Novavax
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Vaccine Type Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Gamaleya Research Institute
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Vaccine Type Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. CanSino Biologics
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Vaccine Type Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. CureVac
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Vaccine Type Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. GlaxoSmithKline
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Vaccine Type Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. Sanofi-GSK
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Vaccine Type Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview